Clive A. Meanwell has been a director since 1996. He has served as our chief executive officer since February 2012, our chief executive officer and president from October 2009 to February 2012, as our chief executive officer from August 2004 to October 2009, as our president from August 2004 to December 2004, our executive chairman from September 2001 to August 2004 and as our chief executive officer and president from 1996 to September 2001. Dr. Meanwell was also chairman of our board from September 2001 to August 2015. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. (British equivalent MB ChB) and a Ph.D. (British equivalent MD hons) from the University of Birmingham, United Kingdom.
Chris Visioli joined The Medicines Company in June 2003. He has worked in a variety of leadership roles in the organization including business development, finance, investor relations, strategy, planning, and business leadership of the anti-platelet team. Chris has led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining MDCO, Chris was a management consultant for Ernst & Young. Chris holds a BS in electrical engineering from Cornell University and an MBA from Columbia Business School.
Chris Cox joined The Medicines Company (MDCO) in February 2016 as Executive Vice President and Chief Corporate Development Officer. Prior to joining MDCO, Chris spent over 20 years as a corporate attorney, most recently at Cadwalader, Wickersham & Taft LLP, where he was Co-Chair of the Firm’s Corporate Group and a member of its Management Committee. He joined Cadwalader in January 2012. Previously, he was a Partner at Cahill Gordon & Reindel LLP. Chris has extensive experience in a wide array of corporate, financial and business-related matters, including mergers and acquisitions, joint ventures, restructurings, spin-offs and IP licensing and monetization transactions. He has been selected by The American Lawyer as a “Dealmaker of the Year” and was named an M&A Atlas "Top 50 Global M&A Lawyer." He has also been recognized for his work in mergers, acquisitions and buyouts by Chambers and The Legal 500 and has been named a leading lawyer by the Lawdragon 500 Annual Guide. Chris has been a Director of Datawatch Corporation since August 21, 2012. He received a B.S. and J.D. from the University of Missouri, where he was a member of the Missouri Law Review.
Nancye Green leads global communications & information architecture for The Medicines Company (MDCO). A designer and business leader, Nancye has had a storied career addressing the complex communication challenges of large enterprises, startup companies and non-profit organizations across industries. She has designed and produced in multiple media on behalf of clients as diverse as Hoffman-La Roche, 3M, P&G, Exxon, the Ronald Reagan Presidential Library, American Express, Sony and American Girl Place, among many others. In addition, Nancye has founded and/or served as CEO of several businesses, including design firm Donovan/Green and Waterworks, and has served on the boards of directors of several companies, including Waterworks and Hallmark. A recognized leader in her field, she is a past president of the American Institute of Graphic Arts and the prestigious International Design Conference in Aspen. She holds degrees from Tulane University and Parsons School of Design, and was awarded an honorary doctorate from The Corcoran School of Art in Washington, D.C.
Loretta Itri joined The Medicines Company (MDCO) in 2012 and leads Global Health Science and Regulatory Affairs. Previously, she was President of Pharmaceutical Development and CMO at Genta, Inc., and prior to that she served as Senior Vice President of Medical and Regulatory Affairs at the Robert Wood Johnson Pharmaceutical Research Institute, where she oversaw the development and approval of a variety of therapeutic compounds. In addition, Loretta served as Senior Vice President of Clinical Affairs and CMO for Ortho Biotech Inc., responsible for the hematology, oncology and immunology product lines. She began her career in the pharmaceutical industry at Hoffman-La Roche, where she advanced to the position of AVP of Clinical Development in immunology, virology, hematology, and oncology. Loretta received her medical degree from New York Medical College and completed her medical residency at SUNY-Stony Brook and her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. She was an adjunct attending physician at MSKCC for over 15 years. She has served as a member of the National Cancer Institute Board of Scientific Counselors in both the Division of Cancer Treatment and the Division of Cancer Prevention and Control. Loretta has authored more than 130 original articles, book chapters and abstracts related to the clinical development of therapeutic agents.
Bill O'Connor has been a Special Advisor to the Chief Executive Officer of The Medicines Company (MDCO) since March 2018. Previously, Bill served as MDCO’s Chief Financial Officer from 2016 to 2018 and Chief Accounting Officer from 2008 to 2016. Before joining MDCO, Bill was the Vice President of Finance for Eyetech Pharmaceuticals, Inc. from 2000 to 2006 and worked in various finance roles at Trophix Pharmaceuticals, Inc. from 1996 to 2000. Prior to 1996, Bill worked in the public accounting sector for approximately 15 years. Bill is a certified public accountant and received his bachelor’s degree in accounting from Fairleigh Dickinson University.
Dr. Stephanie Plent is an Executive Vice President and Chief Value Officer at The Medicines Company. She is responsible for the global health economic development, reimbursement, market access and outcomes research for developing compounds as well as marketed products.
Stephanie joined The Medicines Company in July 2000 to build an economic and medical policy function. She became Vice President of Medical Affairs in 2003 then managed Phase IV programs and pediatric initiatives. In 2008 she led the expansion of bivalirudin into European markets working with the reimbursement agencies to gain positive HTA’s and reimbursement across the European markets.
Stephanie received her medical degree from the Royal Free Hospital, London UK and completed her general surgical residency at St. Bartholomew's Hospital UK. Since moving to the US she worked in the Health Care Practice of the consultancy company, Arthur D. Little, Cambridge MA and then for six years at Aetna Insurance, developing cardiac centers of excellence programs in conjunction with major cardiovascular hospitals and then launched national disease management programs for asthma, diabetes, heart failure and back pain management.
Stephen Rodin has been general counsel and secretary of The Medicines Company since March 2014. Previously he served as the Company's deputy general counsel from 2010 to 2014 and associate general counsel from 2007 to 2010. Before joining The Medicines Company, Steve was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Steve received an A.B. from Georgetown University and his J.D. from Vanderbilt University Law School.